强化降脂治疗对不稳定型心绞痛患者血清超敏C反应蛋白水平的影响及疗效观察  

Influence and curative effect observation of intensive lipid-lowering treatment on serum high sensitive C-reactive protein(hs-CRP) level of patients with unstable angina pectoris(UAP)

作　　者：蓝建明 甘慧玲 童巧薇 罗利飞 

机构地区：[1]浙江省衢州市柯城区人民医院心内科,浙江衢州324000 [2]浙江省台州市恩泽医疗中心(集团)路桥院区检验科,浙江台州318050

出　　处：《中国现代医生》2015年第8期25-27,30,共4页China Modern Doctor

基　　金：浙江省医药卫生科技项目(2012ZHB022)

摘　　要：目的探讨强化降脂治疗对不稳定型心绞痛(UAP)患者血清超敏C反应蛋白(hs-CRP)水平的影响及疗效。方法选取心内科住院治疗的UAP患者84例,采用数字表将其随机分为观察组42例和对照组42例。两组患者均予以抗血小板聚集、扩血管和改善心肌微循环等基础治疗。对照组在此基础上口服阿托伐他汀20 mg/次,1次/d;观察组在此基础上口服阿托伐他汀40 mg/次,1次/d,连用3个月。观察并记录两组治疗前后血清hs-CRP水平的变化,并比较治疗期间心血管不良事件发生率和药物不良反应。结果治疗3个月后,两组患者血清hsCRP水平均明显下降(P<0.05或P<0.01),且观察组下降幅度明显大于对照组(P<0.05);观察组患者治疗中心血管不良事件发生率(4.76%)明显低于对照组(21.43%)(χ2=5.13,P<0.05);两组患者治疗中共发生不良反应8例,对照组3例,观察组发生5例,症状均较轻,两组不良反应发生率比较差异无统计学意义(χ2=0.14,P>0.05)。结论阿托伐他汀强化降脂治疗用于治疗UAP疗效显著,安全性较好,能明显降低心血管不良事件发生率,作用与其降低血清hs-CRP水平,抑制斑块局部炎症反应,增强斑块的稳定性有关。Objective To discuss influence and curative effect observation of intensive lipid-lowering treatment on serum high sensitive C-reactive protein（hs-CRP） level of patients with unstable angina pectoris（UAP）. Methods A total of 84 cases of patients with UAP given the medical treatment and in hospital in cardiology department were selected and divided into 42 cases in observation group and 42 cases in control group by table of number at randomly. The patients in two groups were given basic treatment such as anti-platelet aggregation, expansion of blood vessels, improvement of myocardial microcirculation and etc. The patients in control group were additionally given oral 20 mg atorvastatin per time, once a day, while the patients in observation group were additionally given 40 mg atorvastatin per time,once a day for 3 months. The changes of serum hs-CRP levels before and after medical treatment in two groups were observed and recorded, and the cardiovascular adverse occurrence rates and drug adverse reaction during the medical treatment were compared as well. Results After three months’ medical treatment, serum hs-CRP levels of patients in two groups were obviously declined than before（P 〈0.05 or P 〈0.01）, and the declining rate in observation group was much higher than that in control group（P〈0.05）. The cardiovascular adverse occurrence rate of patients in observation group（4.76%） during the medical treatment was much lower than that in control group（21.43%）（χ2=5.13, P〈0.05）. Eight cases of untoward effect of patients in two groups were appeared in the medical treatment with light symptom, with three and five cases in control group and observation group respectively, and after comparing the occurrence rates of untoward effect of patients in two groups, no obvious statistical differences were appeared（χ2=0.14, P〉0.05）. Conclusion The application of atorvastatin as intensive lipid-lowering treatment has significant curative effect on UAP with favorable security, which can o

关 键 词：不稳定型心绞痛 强化降脂 超敏C反应蛋白 心血管不良事件 

分 类 号：R541.4[医药卫生—心血管疾病]